Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the Société Francophone du Nerf Périphérique Annual Meeting - read this article along with other careers information, tips and advice on BioSpace
- Company to Host Conference Call January 21st at 8:30 am ET to Discuss Results - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company